{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T03:23:21Z","timestamp":1785813801678,"version":"3.56.0"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T00:00:00Z","timestamp":1747440000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>The role of sodium-glucose co-transporter 2 inhibitors (SGLT2i) in patients with cardiac amyloidosis (CA) is controversial. However, they have shown encouraging results in several clinical settings, including heart failure, myocardial infarction, chronic kidney disease, and various forms of restrictive cardiomyopathy. The current study aims to evaluate the tolerability and efficacy of SGLT2i in patients with CA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>PubMed, Scopus, Cochrane Library, and Embase were scanned for eligible articles up to 28th of March 2025. Safety endpoints included the cumulative prevalence of adverse events (AEs) and drug discontinuation (DD) in the SGLT2i-group. Efficacy endpoints were the pooled risk ratio (RR) of all-cause death (ACD) and hospitalization due to worsening heart failure (WHF) between treatment- and control-groups, as well as the difference between mean change of N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels in both treatment- and control-groups. Thirteen observational studies, encompassing 19 227 patients, were included in the meta-analysis. Sodium-glucose co-transporter 2 inhibitors use in patients with CA resulted to be tolerable, as demonstrated by a low absolute cumulative prevalence of both AEs [8%; 95% confidence interval (CI) 2\u201317, nine studies, 603 patients] and DD (4%; 95% CI: 1\u20137, nine studies, 603 patients). Furthermore, its use was associated with a reduction in the risk of ACD (RR 0.59; 95% CI: 0.48\u20130.72) and NT-proBNP levels (median difference: \u2212525.54; 95% CI: \u2212718.09 to \u2212332.98), despite no significant association with WHF was noted.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The administration of SGLT2i proved to be well tolerated in patients with CA. Randomized controlled trials are urgently needed to confirm the prognostic improvement associated with their use in this clinical setting.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Study registration<\/jats:title>\n                  <jats:p>CRD42025632733<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvaf033","type":"journal-article","created":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T15:01:22Z","timestamp":1747494082000},"page":"356-364","source":"Crossref","is-referenced-by-count":7,"title":["Tolerability and efficacy of sodium-glucose co-transporter 2 inhibitors in patients with cardiac amyloidosis: a meta-analysis of observational studies"],"prefix":"10.1093","volume":"11","author":[{"given":"Renzo","family":"Laborante","sequence":"first","affiliation":[{"name":"Department of Clinical Science and Education, S\u00f6dersjukhuset, Karolinska Institutet , Sjukhusbacken 10, 118 83 Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Elia","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine, University of Eastern Piedmont , Via Solaroli 17, Novara 28100 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluigi","family":"Savarese","sequence":"additional","affiliation":[{"name":"Department of Clinical Science and Education, S\u00f6dersjukhuset, Karolinska Institutet , Sjukhusbacken 10, 118 83 Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5404-3968","authenticated-orcid":false,"given":"Giuseppe","family":"Patti","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine, University of Eastern Piedmont , Via Solaroli 17, Novara 28100 ,","place":["Italy"]},{"name":"Thoraco-Cardio-Vascular Department, Azienda Ospedaliero-Universitaria Maggiore della Carit\u00e0 , Corso Mazzini 18, Novara 28100 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"D\u2019Amario","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine, University of Eastern Piedmont , Via Solaroli 17, Novara 28100 ,","place":["Italy"]},{"name":"Thoraco-Cardio-Vascular Department, Azienda Ospedaliero-Universitaria Maggiore della Carit\u00e0 , Corso Mazzini 18, Novara 28100 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,17]]},"reference":[{"key":"2025070708270831400_pvaf033-B1","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1002\/ehf2.14000","article-title":"Incidence and predictors of worsening heart failure in patients with wild-type transthyretin cardiac amyloidosis","volume":"9","author":"Ladefoged","year":"2022","journal-title":"ESC Heart Fail"},{"key":"2025070708270831400_pvaf033-B2","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.amjcard.2024.10.009","article-title":"Cardiac amyloidosis screening and management in patients with heart failure with preserved ejection fraction: an international survey","volume":"236","author":"Shchendrygina","year":"2024","journal-title":"Am J Cardiol"},{"key":"2025070708270831400_pvaf033-B3","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1161\/CIRCULATIONAHA.119.045093","article-title":"Cost-effectiveness of tafamidis therapy for transthyretin amyloid cardiomyopathy","volume":"141","author":"Kazi","year":"2020","journal-title":"Circulation"},{"key":"2025070708270831400_pvaf033-B4","doi-asserted-by":"publisher","first-page":"131598","DOI":"10.1016\/j.ijcard.2023.131598","article-title":"Cost-effectiveness of systematic screening and treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) in patients with heart failure with preserved ejection fraction (HFpEF) in United States","volume":"398","author":"Lau","year":"2024","journal-title":"Int J Cardiol"},{"key":"2025070708270831400_pvaf033-B5","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S2213-8587(24)00102-5","article-title":"Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis","volume":"12","author":"Usman","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025070708270831400_pvaf033-B6","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1093\/ehjcvp\/pvae047","article-title":"Safety and efficacy of early initiation of sodium-glucose cotransporter-2 inhibitors after an acute coronary syndrome event: a meta-analysis of randomized controlled trials","volume":"10","author":"Laborante","year":"2024","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2025070708270831400_pvaf033-B7","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/j.jchf.2024.03.006","article-title":"Cost-effectiveness of medical therapy for heart failure with mildly reduced and preserved ejection fraction","volume":"12","author":"Dixit","year":"2024","journal-title":"JACC Heart Fail"},{"key":"2025070708270831400_pvaf033-B8","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/cvr\/cvae004","article-title":"Hypertrophic cardiomyopathy dysfunction mimicked in human engineered heart tissue and improved by sodium-glucose cotransporter 2 inhibitors","volume":"120","author":"Wijnker","year":"2024","journal-title":"Cardiovasc Res"},{"key":"2025070708270831400_pvaf033-B9","doi-asserted-by":"publisher","first-page":"zwae345","DOI":"10.1093\/eurjpc\/zwae345","article-title":"Sodium-glucose cotransporter-2 inhibitors and clinical outcomes in patients with hypertrophic cardiomyopathy and diabetes: a population-based cohort study","author":"Jung","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"2025070708270831400_pvaf033-B10","doi-asserted-by":"crossref","first-page":"109024","DOI":"10.1016\/j.intimp.2022.109024","article-title":"SGLT2 inhibitor, canagliflozin, ameliorates cardiac inflammation in experimental autoimmune myocarditis","volume":"110","author":"Long","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"2025070708270831400_pvaf033-B11","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejim.2025.01.014","article-title":"Safety and efficacy of early initiation of sodium-glucose co-transporter inhibitors 2 in patients hospitalized for acute heart failure: a meta-analysis of randomized controlled trials","volume":"135","author":"Laborante","year":"2025","journal-title":"Eur J Intern Med"},{"key":"2025070708270831400_pvaf033-B12","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/j.jacc.2024.03.429","article-title":"SGLT2 inhibitor therapy in patients with transthyretin amyloid cardiomyopathy","volume":"83","author":"Porcari","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2025070708270831400_pvaf033-B13","doi-asserted-by":"crossref","first-page":"101405","DOI":"10.1016\/j.jacadv.2024.101405","article-title":"Sodium-glucose cotransporter 2 inhibitor use and outcomes in transthyretin amyloid cardiomyopathy","volume":"3","author":"Jaiswal","year":"2024","journal-title":"JACC Adv"},{"key":"2025070708270831400_pvaf033-B14","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1001\/jamasurg.2021.0522","article-title":"MOOSE reporting guidelines for meta-analyses of observational studies","volume":"156","author":"Brooke","year":"2021","journal-title":"JAMA Surg"},{"key":"2025070708270831400_pvaf033-B15","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2025070708270831400_pvaf033-B16","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2288-5-13","article-title":"Estimating the mean and variance from the median, range, and the size of a sample","volume":"5","author":"Hozo","year":"2005","journal-title":"BMC Med Res Methodol"},{"key":"2025070708270831400_pvaf033-B17","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1177\/0145445516673998","article-title":"Intercoder reliability and validity of WebPlotDigitizer in extracting graphed data","volume":"41","author":"Drevon","year":"2017","journal-title":"Behav Modif"},{"key":"2025070708270831400_pvaf033-B18","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1001\/jama.280.19.1690","article-title":"What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes","volume":"280","author":"Zhang","year":"1998","journal-title":"JAMA"},{"key":"2025070708270831400_pvaf033-B19","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1478-7954-1-4","article-title":"A generic model for the assessment of disease epidemiology: the computational basis of DisMod II","volume":"1","author":"Barendregt","year":"2003","journal-title":"Popul Health Metr"},{"key":"2025070708270831400_pvaf033-B20","doi-asserted-by":"crossref","first-page":"e178","DOI":"10.1002\/hsr2.178","article-title":"Arcsine-based transformations for meta-analysis of proportions: pros, cons, and alternatives","volume":"3","author":"Lin","year":"2020","journal-title":"Health Sci Rep"},{"key":"2025070708270831400_pvaf033-B21","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s11739-022-02944-8","article-title":"SGLT2i in patients with transthyretin cardiac amyloidosis, a well-tolerated option for heart failure treatment? Results from a small, real-world, patients series","volume":"17","author":"Zampieri","year":"2022","journal-title":"Intern Emerg Med"},{"key":"2025070708270831400_pvaf033-B22","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ehf2.14188","article-title":"SGLT2 inhibitor therapy for transthyretin amyloid cardiomyopathy: early tolerance and clinical response to dapagliflozin","volume":"10","author":"Dobner","year":"2023","journal-title":"ESC Heart Fail"},{"key":"2025070708270831400_pvaf033-B23","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3390\/jcm13010283","article-title":"Safety and tolerability of SGLT2 inhibitors in cardiac amyloidosis-a clinical feasibility study","volume":"13","author":"Steinhardt","year":"2024","journal-title":"J Clin Med"},{"key":"2025070708270831400_pvaf033-B24","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/ejhf.3198","article-title":"Sodium-glucose cotransporter 2 inhibitors for transthyretin amyloid cardiomyopathy: analyses of short-term efficacy and safety","volume":"26","author":"Lang","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2025070708270831400_pvaf033-B25","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.rec.2023.10.007","article-title":"Use of SGLT2i in patients with transthyretin amyloid cardiomyopathy: prevalence and safety in a Spanish prospective cohort","volume":"77","author":"Gonz\u00e1lez-Montes","year":"2024","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"2025070708270831400_pvaf033-B26","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/j.cardfail.2024.06.009","article-title":"Safety and efficacy of SGLT2 inhibitors for amyloid light-chain cardiomyopathy","volume":"30","author":"Lang","year":"2024","journal-title":"J Card Fail"},{"key":"2025070708270831400_pvaf033-B27","doi-asserted-by":"crossref","first-page":"5966","DOI":"10.3390\/jcm13195966","article-title":"Impact of SGLT2-inhibitor therapy on survival in patients with transthyretin amyloid cardiomyopathy: analysis of a prospective registry study","volume":"13","author":"Schwegel","year":"2024","journal-title":"J Clin Med"},{"key":"2025070708270831400_pvaf033-B28","first-page":"e72725","article-title":"The role of sodium-glucose cotransporter-2 inhibitors in adults with transthyretin cardiac amyloidosis: a single-center retrospective cohort study","volume":"16","author":"Pillai","year":"2024","journal-title":"Cureus"},{"key":"2025070708270831400_pvaf033-B29","doi-asserted-by":"publisher","first-page":"S1547-5271(24)03292-2","DOI":"10.1016\/j.hrthm.2024.09.002","article-title":"Impact of SGLT2 inhibitors on the outcomes of patients with cardiac arrhythmias and transthyretin cardiac amyloidosis","author":"Sivamurugan","year":"2024","journal-title":"Heart Rhythm"},{"key":"2025070708270831400_pvaf033-B30","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.amjmed.2025.02.010","article-title":"Sodium-glucose cotransporter 2 inhibitors in patients with amyloidosis with or without heart failure","volume":"138","author":"Augusto","year":"2025","journal-title":"Am J Med"},{"key":"2025070708270831400_pvaf033-B31","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.amjcard.2025.01.012","article-title":"Impact of sodium-glucose cotransporter-2 inhibitors on cardiovascular outcomes in transthyretin amyloid cardiomyopathy","volume":"243","author":"Byer","year":"2025","journal-title":"Am J Cardiol"},{"key":"2025070708270831400_pvaf033-B32","doi-asserted-by":"crossref","first-page":"e14392","DOI":"10.1111\/eci.14392","article-title":"Sodium-glucose cotransporter 2 inhibitors and outcomes in transthyretin amyloid cardiomyopathy: systematic review and meta-analysis","volume":"55","author":"Karakasis","year":"2025","journal-title":"Eur J Clin Invest"},{"key":"2025070708270831400_pvaf033-B33","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/ehf2.14633","article-title":"Safety of sodium-glucose cotransporter 2 inhibitors drugs among heart failure patients: a systematic review and meta-analysis","volume":"11","author":"Soleimani","year":"2024","journal-title":"ESC Heart Fail"},{"key":"2025070708270831400_pvaf033-B34","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1007\/s11255-023-03789-6","article-title":"Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients with chronic kidney disease: a systematic review and meta-analysis","volume":"56","author":"Shiau","year":"2024","journal-title":"Int Urol Nephrol"},{"key":"2025070708270831400_pvaf033-B35","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2025070708270831400_pvaf033-B36","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"2025070708270831400_pvaf033-B37","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases","volume":"42","author":"Garcia-Pavia","year":"2021","journal-title":"Eur Heart J"},{"key":"2025070708270831400_pvaf033-B38","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","article-title":"Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association","volume":"142","author":"Kittleson","year":"2020","journal-title":"Circulation"},{"key":"2025070708270831400_pvaf033-B39","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s00392-019-01490-2","article-title":"When and how do patients with cardiac amyloidosis die?","volume":"109","author":"Escher","year":"2020","journal-title":"Clin Res Cardiol"},{"key":"2025070708270831400_pvaf033-B40","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1080\/13506129.2021.2013193","article-title":"Describing mode of death in three major cardiac amyloidosis subtypes to improve management and survival","volume":"29","author":"Kharoubi","year":"2022","journal-title":"Amyloid"},{"key":"2025070708270831400_pvaf033-B41","doi-asserted-by":"crossref","first-page":"11519","DOI":"10.3390\/ijms252111519","article-title":"Heart failure with preserved ejection fraction and cardiac amyloidosis in the aging heart","volume":"25","author":"Tana","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2025070708270831400_pvaf033-B42","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1161\/CIRCULATIONAHA.122.061732","article-title":"Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling\/autophagy hypothesis","volume":"146","author":"Packer","year":"2022","journal-title":"Circulation"},{"key":"2025070708270831400_pvaf033-B43","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1161\/CIRCULATIONAHA.123.064346","article-title":"Critical analysis of the effects of SGLT2 inhibitors on renal tubular sodium, water and chloride homeostasis and their role in influencing heart failure outcomes","volume":"148","author":"Packer","year":"2023","journal-title":"Circulation"},{"key":"2025070708270831400_pvaf033-B44","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.hrthm.2021.03.028","article-title":"Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: a meta-analysis of 34 randomized controlled trials","volume":"18","author":"Fernandes","year":"2021","journal-title":"Heart Rhythm"},{"key":"2025070708270831400_pvaf033-B45","doi-asserted-by":"crossref","first-page":"e24298","DOI":"10.1002\/clc.24298","article-title":"Predictors of developing renal dysfunction following diagnosis of transthyretin cardiac amyloidosis","volume":"47","author":"McDonald","year":"2024","journal-title":"Clin Cardiol"},{"key":"2025070708270831400_pvaf033-B46","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1002\/ejhf.2967","article-title":"Sodium\u2013glucose cotransporter-2 inhibitors in heart failure: potential decongestive mechanisms and current clinical studies","volume":"25","author":"Biegus","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2025070708270831400_pvaf033-B47","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system","volume":"68","author":"Grogan","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2025070708270831400_pvaf033-B48","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.jacc.2023.12.036","article-title":"Stratifying disease progression in patients with cardiac ATTR amyloidosis","volume":"83","author":"Ioannou","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2025070708270831400_pvaf033-B49","doi-asserted-by":"crossref","first-page":"100843","DOI":"10.1016\/j.jacadv.2024.100843","article-title":"Impact of sodium-glucose cotransporter 2 inhibitors on mortality in hypertrophic cardiomyopathy","volume":"3","author":"Aglan","year":"2024","journal-title":"JACC Adv"},{"key":"2025070708270831400_pvaf033-B50","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.amjcard.2022.10.054","article-title":"Efficacy of SGLT2 inhibitors in patients with diabetes and nonobstructive hypertrophic cardiomyopathy","volume":"188","author":"Subramanian","year":"2023","journal-title":"Am J Cardiol"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvaf033\/63153354\/pvaf033.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/11\/4\/356\/63153354\/pvaf033.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/11\/4\/356\/63153354\/pvaf033.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T12:27:20Z","timestamp":1751891240000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/11\/4\/356\/8128807"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,17]]},"references-count":50,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,5,17]]},"published-print":{"date-parts":[[2025,7,7]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvaf033","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,5,17]]}}}